Broth dilution susceptibility tests of 100 isolates of Pseudomonas aeruginosa and 101 isolates of Staphylococcus aureus against tobramycin (formerly nebramycin factor 6) and gentamicin showed that tobramycin was more effective against P. aeruginosa and less effective against S. aureus. The minimal inhibitory concentration of tobramycin against the Pseudomonas sp. isolates that required 5 ,g of gentamicin per ml for inhibition ranged from 0.63 to 0.31 Mg/ml. Peak concentrations in the blood of 10 healthy adults after intramuscular injection of 80 and 40 mg of tobramycin averaged 3.7 0.62 and 2.4 0.27 ,ug/ml, and declined to 0.56 i 0.05 and 0.26 i 0.02 ug/ml, respectively, after 6 h.
The urine recovery averaged 60%. The half-life was 1.6 h. During continuous intravenous infusion of tobramycin and gentamicin (infusion rate 6.6 mg per h), blood levels at steady state were 0.94 0.10 and 1.04 i 0.06 Mg/ml, respectively. For both antibiotics, the calculated distribution volume ranged from 15 to 17 liters. The renal clearance of tobramycin averaged 76% and that of gentamicin averaged 85% of the total clearance, indicating that the drugs are primarily eliminated by the kidneys. The present results suggest that tobramycin may be more successful in the treatment of Pseudomonas infections than gentamicin at the same dosage (80 mg intramuscularly three to four times daily).
Nebramycin, an antibiotic complex of at least seven factors, was first described in 1967 by Stark et al. (20) . Nebramycin belongs to the aminoglycosidic family of antibiotics, which includes kanamycin, neomycin, gentamicin, and paromomycin. The antibiotic complex is produced by fermentation biosynthesis with the use of Streptomyces tenebrarius (11) . Chromatographic studies have shown that the complex consists of factors 1, 1', 2, 3, 4, 5, and 6 (22) . Factors 1, 1', and 3 are found only in small amounts and are, therefore, not significant. Of special interest was factor 6 of the nebramycin complex (tobramycin), because it had a favorable antibacterial spectrum and the best in vitro activity of any of the factors. The toxicity of tobramycin is slightly greater than that of the complex and of factor 2. Wick and Welles (25) compared the nephrotoxicity of tobramycin and gentamicin in rats and found that tobramycin was less nephrotoxic than gentamicin (evidenced by urine glutamic oxalacetic transaminase concentrations, renal tubular cell excretion, and histopathological examination of renal tissue). As with other aminoglycoside antibiotics, ototoxic side effects (especially vestibular damage) were produced by higher doses in animal studies. Overall, it appears that the toxicity of tobramycin is similar to that of kanamycin and less than that of neomycin B and gentamicin.
Tobramycin, which had been isolated from the nebramycin complex, was made available in purified form. The molecular formula of tobramycin is C18H87N,O0 .3H20 (14) . The antibiotic is a colorless, hygroscopic substance which is very soluble in water. The crystalline form is available as mono-, di-, or trihydrate. (17) found that the test results are also affected by the agar content; thus, inhibitory concentrations of tobramycin are far lower in nutrient broth than in an agar-containing medium.
Black and Griffith (2) reported on serum levels after intramuscular injection of tobramycin and showed that, independently of the dosage, peak concentrations in serum were achieved in 30 min. Also, after the administration of 25, 50, and 75 mg, mean serum concentrations of tobramycin were 0.26, 0.56, and 0.90 ,ug/ml, respectively, after 4 h (concentrations were proportionate to the dose). When comparing the serum levels of gentamicin and tobramycin after intramuscular injection of corresponding doses, these same authors found that gentamicin serum concentrations were not significantly higher than those for tobramycin. An average of 38.3% of administered antibiotic was found in urine after intramuscular injection of 75 mg of tobramycin. Accordingly, these investigators concluded that there was no significant difference in the calculated elimination constants and distribution coefficients of tobramycin and gentamicin.
The purpose of this paper is to compare the antibacterial activity of tobramycin with that of gentamicin, especially against P. aeruginosa and S. aureus. Determinations were also made of the pharmacokinetic constants of tobramycin (elimination constants, area under the blood level curve, and distribution volume) to assess the properties of this new antibiotic. From the serum levels obtained and the halflife calculated, recommendations might be ANTIMICROB. AG. CHEMOTHER.
made for an optimal dosage of tobramycin for intramuscular injection and for continuous intravenous infusion.
MATERIALS AND METHODS Bacteria. Cultures of P. aeruginosa (100 isolates) and S. aureus (101 isolates) tested in this study were obtained from clinical specimens at the Pediatric University Clinic, Kiel, Germany.
MIC determinations. For MIC determinations, all isolates of Pseudomonas sp. and Staphylococcus sp. were incubated overnight in nutrient broth at 37 C. On the next day, tubes containing decreasing concentrations in log2 dilutions of tobramycin or gentamicin (20 to 0.04 ig/ml) in a liquid medium (Antibiotic Medium 3, Difco; Penassay broth) were inoculated with 0.1 ml of a 1:100 dilution from each culture. After incubation for 18 h at 37 C, the MIC was read as the lowest concentration of antibiotic inhibiting visible growth.
Human volunteers. Subjects used in the 33 blood level studies of tobramycin and gentamicin were 18 healthy males, 21 to 43 years old, weighing 65 to 90 kg. None of the volunteers had received any prior medication.
Procedure for obtaining serum or urine specimens. Tobramycin (Eli Lilly & Co.) and gentamicin (Refobacin; Merck, Darmstadt, Germany) were available in ampoule form. Ampoules of tobramycin contained 50 mg of base per ml; ampoules of gentamicin contained 40 mg. Administration consisted of a single intramuscular injection of varied doses of tobramycin, or continuous infusion over 4 h with the infusion rate at 6.6 mg per h in 6 ml of solution. Solutions of tobramycin and gentamicin were diluted in infusion solution, Tutofusin NS (Pfrimmer). Uniformity of the infusion rate was assured by use of an adjustable perfusor (Braun, Melsungen). At the end of the infusion period, a previously calculated rest volume was left in the perfusor. After intramuscular administration, blood was withdrawn at 15-min intervals during the first hour, at 30-min intervals until the sixth hour, and after 8 and 12 h. During continuous intravenous infusion, blood samples were taken at 15-min intervals during the first hour, at 30-min intervals until the fourth hour, after termination of the infusion at 15, 30, and 60 min, and then at intervals of 30 min until the seventh hour.
After intramuscular administration, urine was collected over 3-h periods until the twelfth hour, the volume was recorded, and the antibiotic concentration in each portion was determined. The amount of antibiotic excreted was calculated from the volume and the concentration. During continuous intravenous infusion, portions of urine were collected during the first 3 h, during the fourth hour, and during the fifth to seventh hours.
Microbiological assay. 1.25 ,gg/ml, whereas 67% of the isolates were inhibited by gentamicin at a MIC of 0.31 ,g/ml. The relatively wide range in the in vitro susceptibility of S. aureus to tobramycin is striking. Sixteen percent of the isolates of staphylococcus that required concentrations of 2.5 Ag of tobramycin per ml for inhibition were more susceptible, by the method used, to gentamicin by 2 to 3 geometric dilutions.
The in vitro susceptibility tests for a larger number of cultures of pseudomonads and staphylococci demonstrate that tobramycin is definitely more effective than gentamicin against P. aeruginosa, whereas gentamicin appears more active, in vitro, against S. aureus.
Pharmacokinetics. After intramuscular in- ,gg/ml after 80 mg), as is shown in Table 2 (Fig. 3) .
In accordance with the rapid absorption, mathematic calculation yielded a relatively high absorption constant of 4.0 to 4.9 (Table 3) and, as can be expected from the relatively rapid decline of the serum concentration curve, an elimination constant of 0.43, which corresponded to a biological half-life of 1.6 h. The area under the blood concentration curve increased from an average of 6.8 to 11.9 h .ag/ml when the dosage was doubled, indicating that serum levels were proportionate to the dose.
The highest urine concentrations (Table 4) were achieved during the first 3 h (60 to 115 Ag/ml after 40 mg and 90 to 500 Ag/ml after 80 mg). During the second and third 3-h period, urine levels were considerably lower; however, they still exceeded the MIC values for the isolates of Pseudomonas and Staphylococcus tested. Between the 10th and 12th h, tobramycin was no longer demonstrable in the urine after the dosage of 40 mg, whereas urine When the same dosage of gentamicin was given by continuous intravenous infusion over 4 h (infusion rate, 6.6 mg/h), values corresponding to tobramycin were observed (Table 5 ). There was no significant difference when assuming a 1% error probability. During continuous infusion of gentamicin, the blood level, at steady state, averaged 1.04 ,g/ml, the elimination constant was 0.41 (corresponding to a half-life of 1.7 h), and the area under the blood concentration curve was 5.19 h .yg/ml). The distribution volume was calculated to be 14.4 liters and thus somewhat lower than that of tobramycin, but the difference was not significant. The distribution coefficient was found to be 0.21.
From the clearance studies performed during continuous intravenous infusion of tobramycin and gentamicin, the total clearance of tobramycin averaged 115.7 ml/min, and the total clearance of gentamicin averaged 95.8 ml/min (no significant difference). The renal clearance was 87.9 ml/min for tobramycin and 81.8 mV min for gentamicin (76 and 85% of total clearance). The resulting mean value of extrarenal clearance is 24% and 15%, respectively (difference not significant). The average urine recovery during the fourth hour after the beginning of the infusion was found to be 59.2% of tobramycin and 60.2% of gentamicin.
DISCUSSION
In accordance with the literature (2, 17, 25) , the in vitro activity of tobramycin against 100 
